Ad
related to: novartis- Get Treatment Resources
See Tools Specifically For Patients
About Dosing, Savings And More.
- Important Safety Info
Learn About Possible Side Effects
And View Important Safety Info.
- Helpful Patient Tools
Find Information For Patients Here.
Visit The Official Patient Website.
- Helpful Resources
Learn About An HIV Treatment
And Discover More About Dosing.
- Get Treatment Resources
Search results
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
Zacks· 17 hours agoNovartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
Novartis leukemia drug more effective than older treatments in trial
Reuters via AOL· 10 hours agoSwiss drugmaker Novartis said patients with a type of leukemia who took its Scemblix had a...
Novartis Sues to Block Maryland's New Drug Discount Law - Novartis (NYSE:NVS)
Benzinga· 4 hours agoNovartis AG NVS has reportedly filed a lawsuit to block a Maryland law requiring drugmakers to offer...
Novartis reports Phase III data for trials of remibrutinib to treat CSU
Clinical Trials Arena via Yahoo Finance· 11 hours agoNovartis has released new data from two Phase III clinical trials confirming the sustained efficacy...
Novartis' Oral Drug For Chronic Skin Disease Candidate Shows Efficacy, Long-term Safety - Novartis...
Benzinga· 7 hours agoOn Friday, Novartis AG NVS released new data that confirm the long-term efficacy and safety of...
Novartis study points to larger role for targeted leukemia drug
BioPharma Dive via Yahoo Finance· 14 hours agoThe results are from a late-stage clinical trial run by Scemblix’s maker, Novartis, and will be...
Novartis sues Maryland over law prohibiting restrictions on 340B drugs
Becker’s Hospital Review· 15 hours ago"Novartis sues Maryland over new law restricting 340B drug pricing program, citing conflict with federal law and potential harm to constitutional rights."
Novartis sues Maryland over law mandating discounts for hospitals' outside pharmacies
Reuters· 1 day agoLike other...
Novartis stock rated 'Buy' by Goldman Sachs, highlighting robust innovation By Investing.com
Investing.com· 2 days agoOn Thursday, Goldman Sachs (NYSE:GS) initiated coverage on Novartis AG (SIX:NOVN) stock, listed as...
Novartis (NVS) Presents Positive Data on Renal Drugs at ERA
Zacks· 5 days agoNovartis (NVS) presents data on Fabhalta in adult patients with C3 glomerulopathy and atrasentan in...